Additionally, CARMN functions as a tumor suppressor in cancers such as hepatocellular carcinoma, bladder cancer, and breast cancer, where its regulatory roles in cell invasion, migration, and proliferation highlight its potential as a beneficial biomarker and therapeutic target. This evidence concerns the gene CARMN and urinary bladder carcinoma.